Residual disease post neoadjuvant chemo-immunotherapy in early triple-negative breast cancer: Does it help tailor adjuvant treatment?

Auteurs

Agostinetto E, Buisseret L, Salgado R, Kok M, Ignatiadis M

  • Date de publication

    Maart 2024

  • Type

    Editorial Material

  • Tijdschrift

    Ann Oncol

  • Naam van de onderzoeker

    AGOSTINETTO ELISA

  • Hôpital

    Institut Jules Bordet

  • Dienst

    Academic trials promoting Team, Direction administrative de la recherche, Médecine Oncologique

  • PMID

    38484973

  • DOI

    10.1016/j.annonc.2024.03.003